Spanish biotech company AB-BIOTICS has reached several licensing agreements to distribute its probiotic AB-Life in different markets of Latin America.
AB-BIOTICS has signed a contract with Biolab, the second most important Brazilian pharmaceutical laboratory and a leader in the prescription cardiovascular drug market, to distribute AB-Life in Brazil. The operation will bring the Spanish biotech firm a minimum volume of business of €2.5 millions for the 2012-2016 period. The company has also signed a contract with Laboratorios Leti SAV to market the same product in Venezuela.
AB-BIOTICS has just reached an agrement with Armstrong Laboratorios to distribute AB-Life in Mexico. The operation will bring AB-BIOTICS a business of about 2.3 million euros during the first three years of marketing the product, which will be launched in the Mexican market in late 2012.
"AB-BIOTICS has already reached four license agreements this year, which demonstrates the company's international expansion and the interest aroused by our products", said Miquel Angel Bonachera and Sergi Audivert, CEOs of AB-BIOTICS.
AB-BIOTICS signed its first international contract with the Slovenian firm INSPHARMA, which has the rights to distribute AB-Life in Southeast Europe, particularly in the markets of Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Montenegro, Macedonia and Albania. The Spanish lab Lacer Pharma has the exclusive pharma distribution rights of the product in Spain and Andorra.
AB-Biotics reserves commercialization rights for itself or potential third parties in the food sector, where this probiotic can be added to products without thermal treatment like dairy products or, using encapsulation techniques, to beverages and juices.